Instil Bio reports Q2 2026 results, says it is weighing acquisitions and in-licensing deals

Instil Bio, Inc. released its second quarter 2026 financial results and a corporate update on August 13, 2026. The company said it is evaluating potential acquisitions, in-licensing and related opportunities that may provide access to promising novel therapeutic candidates.¹ No specific targets, timelines, or trial updates were disclosed in the release.

On the balance sheet, Instil reported a cash position of approximately $69.9 million as of June 30, 2026, which it said is expected to fund its current operating plan beyond 2027.¹ That figure compares with the prior year end, when Instil held $76.3 million in cash, cash equivalents, restricted cash and marketable securities as of December 31, 2025.¹

The company reiterated the runway statement in more detail, saying its cash, cash equivalents, restricted cash and marketable securities as of June 30, 2026 will enable it to fund its operating plan beyond 2027.¹

Spending fell sharply from the prior-year period. In-process research and development expenses were nil for the three and six months ended June 30, 2026, compared to $10.0 million for both periods in 2025.¹ Research and development expenses were $0.3 million and $0.9 million for the three and six months ended June 30, 2026, respectively, down from $6.7 million and $12.1 million in the comparable 2025 periods.¹

The release did not describe any clinical trial results, regulatory filings, or program-specific milestones for the quarter. Instil's forward-looking language noted that its plans are subject to risks and uncertainties related to pursuing potential transactions to acquire companies or equity interests therein or in-license product candidates, and the sufficiency of Instil's cash resources.¹